ClinConnect ClinConnect Logo
Search / Trial NCT06307509

Adiposity and Immunometabolism in Sepsis

Launched by NHS GREATER GLASGOW AND CLYDE · Mar 11, 2024

Trial Information

Current as of August 19, 2025

Not yet recruiting

Keywords

Obesity Adipose Tissue Sepsis Critical Illness

ClinConnect Summary

This clinical trial, titled "Adiposity and Immunometabolism in Sepsis," aims to explore how obesity affects patients who are critically ill with sepsis, a serious infection that can lead to organ failure. The researchers want to understand how body fat and inflammation interact in both lean and obese patients with sepsis, comparing their results to healthy individuals. By examining tissue samples and blood from patients undergoing emergency abdominal surgery or admitted to critical care for sepsis, the study hopes to uncover important insights into how obesity may influence the severity of sepsis and inform better treatment strategies.

To participate in this study, candidates must be adults aged 65 to 74 who are either undergoing emergency surgery or have been diagnosed with sepsis based on certain medical criteria. However, individuals who are very ill, pregnant, or unable to give consent will not be eligible. Participants can expect to provide blood samples and small tissue samples for analysis, which will help researchers learn more about the relationship between body fat, inflammation, and sepsis. This trial is currently not recruiting, but it represents an important step in understanding how obesity may impact critical illness.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • For patients in a critical care unit:
  • Diagnosis of sepsis by the criteria set out in the Sepsis-3 guidelines:
  • 1. Suspected diagnosis of infection
  • 2. Acute change in Sequential Organ Failure Assessment (SOFA) of ≥2
  • For patients undergoing an operation:
  • Undergoing emergency abdominal surgery
  • Diagnosis of sepsis by the criteria set out in the Sepsis-3 guidelines:
  • 1. Suspected diagnosis of infection
  • 2. Acute change in Sequential Organ Failure Assessment (SOFA) of ≥2
  • Exclusion Criteria:
  • Patient moribund and death is perceived to be imminent
  • ≥48 hours from diagnosis with sepsis
  • Pregnancy
  • Prisoners
  • Receiving treatment-dose anticoagulant medication
  • Declined consent

About Nhs Greater Glasgow And Clyde

NHS Greater Glasgow and Clyde (NHS GG&C) is one of the largest health organizations in the UK, dedicated to delivering high-quality healthcare services to a diverse population. As a clinical trial sponsor, NHS GG&C plays a pivotal role in advancing medical research and improving patient outcomes through innovative clinical studies. The organization is committed to upholding rigorous ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost care for participant safety and scientific integrity. With a focus on collaboration, NHS GG&C partners with academic institutions, healthcare professionals, and industry stakeholders to foster an environment conducive to groundbreaking research and the development of new therapies.

Locations

Glasgow, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Malcolm Watson, MBChB, PhD

Principal Investigator

NHS Greater Glasgow & Clyde

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported